Human monoclonal antibodies in cancer therapy: A review of recent developments

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 765-772

  Xin, Lin ^a   Cao, Jiaqing ^a   Cheng, Hua ^a   Zeng, Fei ^a   Hu, Xiaoyun ^a   Shao, Jianghua ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Ab dependent cellular cytotoxicity; Monoclonal antibodies; Review; TRAIL R1

Indexed keywords

ANGIOPOIETIN 2; HYBRID PROTEIN; INTETUMUMAB; L19MTNFALPHA PROTEIN; MAPATUMUMAB; MONOCLONAL ANTIBODY; PAM 1 MONOCLONAL ANTIBODY, HUMAN; PAM-1 MONOCLONAL ANTIBODY, HUMAN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; BIOSYNTHESIS; CELL SURFACE DISPLAY; HUMAN; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL SURFACE DISPLAY TECHNIQUES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECOMBINANT FUSION PROTEINS;

MLCS; MLOWN;

EID: 84878808053     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4139     Document Type: Review

References (49)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-7. (1975)
2. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 21, 383-90. (2000)
3. Lonberg N, Huszar D. Human antibodies from transgenic mice. Int. Rev. Immunol 13 (1), 65-93. (1995) (Pubitemid 126837085)
4. Huls G, Gestel D, van der Linden J, Moret E, Logtenberg T. Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies. Cancer Immunol Immunother 50(3), 163-71. (2001) (Pubitemid 32480561)
5. Fujiki T, Tsuji A, Matsumoto SE, Yamashita M, Teruya K, Shirahata S, Katakura Y. Generation of a human antitumor necrosis factor-α monoclonal antibody by in vitro immunization with a multiple antigen peptide. Biosci Biotechnol Biochem 74(9), 1836-40. (2010)
6. Wu H, Pancook JD, Beuerlein G, Chilton T, Pecht G, Huse WD, Watkins JD. Cloning, isolation and characterization of human tumor in situ monoclonal antibodies. Cancer Immunol Immunother 51(2), 79-90. (2002) (Pubitemid 34230722)
7. Dall'Acqua W, Carter P. Antibody engineering. Curr Opin Struc Biol 8, 443-450. (1998) (Pubitemid 28409953)
8. Lamla T, Erdmann VA. Searching sequence space for high affinity binding peptides using ribosome display. J Mol Biol 329, 381-388. (2003) (Pubitemid 36561592)
9. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22, 575-582. (2004) (Pubitemid 38590636)
10. Amstutz P, Pelletier JN, Guggisberg A, Jermutus L, Cesaro-Tadic S, et al. In vitro selection for catalytic activity with ribosome display. J Am Chem Soc 124, 9396-9403. (2002) (Pubitemid 34856226)
11. Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Nati Acad Sci 91, 9022-9026. (1994)
12. Sun Y, Ning B, Liu M, Gao X, Fan X, Liu J, Gao Z. Selection of diethylstilbestrol-specific single-chain antibodies from a non-immunized mouse ribosome display library. PLoS One 7(3), e33186. (2012)
13. Dreier B, Plückthun A. Ribosome display: a technology for selecting and evolving proteins from large libraries. Methods Mol Biol 687, 283-306. (2011)
14. Chodorge M, Fourage L, Ravot G, Jermutus L, Minter R. In vitro DNA recombination by L-Shuffling during ribosome display affinity maturation of an anti- Fas antibody increases the population of improved variants. Protein Eng Des Sel 21(5), 343-51. (2008)
15. Beaber JW, Tam EM, Lao LS, Rondon IJ. A new helper phage for improved monovalent display of Fab molecules. J Immunol Methods 376(1-2), 46-54. (2012)
16. Yuan Q, Wang Z, Nian S, Yin Y, Chen G, Xia Y. Screening of high-affinity scFvs from a ribosome displayed library using BIAcore biosensor. Appl Biochem Biotechnol 152(2), 224-34. (2009)
17. Contreras-Martínez LM, DeLisa MP. Intracellular ribosome display via SecM translation arrest as a selection for antibodies with enhanced cytosolic stability. J Mol Biol 372(2), 513-24. (2007) (Pubitemid 47267955)
18. He M, Taussig MJ. Selection of recombinant antibodies by eukaryotic ribosome display. Methods Mol Biol 484, 193-205. (2008)
19. Azizi A, Arora A, Markiv A, Lampe DJ, Miller TA, Kang AS. Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies. Appl Environ Microbiol 78(8), 2638-47. (2012)
20. Osada E, Shimizu Y, Akbar BK, Kanamori T, Ueda T. Epitope mapping using ribosome display in a reconstituted cell-free protein synthesis system. J Biochem 145(5), 693-700. (2009)
21. Hufton SE. Affinity maturation and functional dissection of a humanised anti-RAGE monoclonal antibody by ribosome display. Methods Mol Biol 805, 403-22. (2012)
22. Thom G, Minter R. Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display. Methods Mol Biol 805, 393-401. (2012)
23. Zhao XL, Chen WQ, Yang ZH, Li JM, Zhang SJ, Tian LF. Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display. J Biotechnol 144(4), 253-8. (2009)
24. Zhao XL, Chen WQ, Li JM, Zhang SJ, Tian LF, Wang L, Gong JB, Yang ZH. Preparation of human antibodies to TNF-alpha using ribosome display technology. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25(2), 145-9. (2009)
25. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 114(3), 426-32. (2005) (Pubitemid 40279964)
26. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4(3), 369-79. (2005) (Pubitemid 40443922)
27. Aoki M, Saikawa Y, Hosokawa S, Fukuda K, Kumai K, Kubota T, Yoshida M, Otani Y, Kitajima M. A novel human monoclonal antibody derived from tumorinfiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes. Anticancer Res 25(6B), 3791-8. (2005)
28. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73(8), 2013-26. (1994) (Pubitemid 24107952)
29. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP. CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 11(4), 777-84. (2004)
30. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11), 2405-13. (2008) (Pubitemid 351590471)
31. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40(5), 1321-30. (2012)
32. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24), 8912-21. (2003) (Pubitemid 38064071)
33. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11(5):2063-73. (2005) (Pubitemid 40471873)
34. Runnels HA, Arbuckle JA, Bailey KS, Nicastro PJ, Sun D, Pegg JA, Meyer DM, Evans M, Bono CP, Lie WR, Moffat MA, Casperson GF, Lennard S, Elvin J, Vaughan T, Smith CE, Morton PA. Human monoclonal antibodies to the insulinlike growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies. Adv Ther 27(7):458-75. (2010)
35. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16(8), 2458-65. (2010)
36. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4, 915-25. (2003) (Pubitemid 37493640)
37. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2(4):289-300. (2002) (Pubitemid 37328782)
38. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66(3), 1721-9. (2006)
39. van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia 11(4), 355-64. (2009)
40. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics 20(5-6), 305-12. (2001) (Pubitemid 34756999)
41. Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19(10), 471-8. (2006) (Pubitemid 44408907)
42. Parren PW, van de Winkel JG.An integrated sciencebased approach to drug development. Curr Opin Immunol .20(4), 426-30. (2008)
43. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol 129(6), 341-8. (2003) (Pubitemid 36963196)
44. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186(3), 1840-8. (2011)
45. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13(7), 2128-35. (2007) (Pubitemid 46649882)
46. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25(11), 1390-5. (2007)
47. Goel S, Bauer RJ, Desai K, Bulgaru A, Iqbal T, Strachan BK, Kim G, Kaubisch A, Vanhove GF, Goldberg G, Mani S. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Ann Oncol 18(10), 1704-7. (2007)
48. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a firstin- human study of patients with advanced solid tumors. Clin Cancer Res 16(2), 699-710. (2010)
49. Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, González-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F. Isolated limb perfusion with the tumortargeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol. (Epub ahead of print) (2012)